TCBP Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients
Portfolio Pulse from
TC BioPharm (NASDAQ: TCBP) has completed the final dosing of 3 patients in its ACHIEVE Phase 2b clinical trial for TCB008, targeting AML and MDS/AML. No drug-related adverse events were reported, indicating a positive step in the trial's progress.
December 20, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TC BioPharm has successfully completed the final dosing of 3 patients in its ACHIEVE Phase 2b trial for TCB008, with no adverse events reported. This marks a positive development in the trial's progress for treating AML and MDS/AML.
The completion of the final dosing in the Phase 2b trial without adverse events is a significant milestone for TC BioPharm. It suggests the potential efficacy and safety of TCB008, which could lead to further positive developments and investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100